A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC 702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2013
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov record.